ARTICLE | Company News
Huahai gets license to Eutilex's EU-101
November 6, 2017 10:24 PM UTC
Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau.
Eutilex received a $30 million equity investment and is eligible for up to $35 million in milestones, plus royalties...